Bioequivalence and Interchangeability: Implications for a Provincial Formulary

Eugenia Palylyk-Colwell, Ph.D.
Scientific Advisor, Expert Committee on Drug Quality and Therapeutics, Alberta Health

CSPS Symposium on Bioequivalence of Drugs with Special Characteristics, Ottawa, ON February 13 & 14, 1998
Bioequivalence

- “a high degree of similarity in the bioavailabilities of two products (of the same galenic form) from the same molar dose, that are unlikely to produce clinically relevant differences in therapeutic effects, or adverse effects, or both”

  (Conduct and Analysis of BA and BE Studies, Part A, Health Canada)

- “a Notice of Compliance issued in respect of a new drug ...... shall state the name of the Canadian Reference Product referred to in the submission and shall constitute a declaration of equivalence for that new drug”

  (Subsection C.08.004 (4), Food and Drug Regulations)
Interchangeability

- “decisions respecting interchangeability and drug lists remain in the domain of the institution responsible for the costs of the product which includes hospitals, provincial governments and other third party payers”

  (Canada Gazette, Part II, September 6, 1995)

- interchangeability requires consideration of whether or not the generic drug exactly fulfills the purposes of the brand name drug, achieves all the beneficial results the brand name drug would have achieved and has no negative side-effects that the brand name drug would have avoided ..... and that in every way, the generic drug ‘does no harm’ when used interchangeably in the individual or in the target population
Harmonization Efforts

- In principle, all provinces support harmonization e.g. development of a list of ‘core submission requirements’

- In reality, interchangeability is a provincial accountability issue

- For subsequent-entry products, in some provinces if a ‘declaration of equivalence’ has been made for Report A drugs and the Canadian Reference Product is identical to the Ministry’s original product, less information is required; comparative bioavailability data is still reviewed for Report B and C drugs
Burden of Proof:
The Standard *In Vivo* Bioequivalence Trial?

- **Inclusion Criteria:**
  - *objective is the reduction of intrasubject variability*
    - age range 18-55 yrs
    - height/weight ratio within 15% of normal
    - healthy adult males

- **Study Design:**
  - *objective is to minimize variability and bias*
    - exercise, diet, smoking, alcohol use
    - administration of food and fluid
    - posture and physical activity
## Population Covered by the Alberta Health Sponsored Drug Programs 1995/96

<table>
<thead>
<tr>
<th>Age in Years</th>
<th>Female</th>
<th>Male</th>
<th>Total</th>
<th>% of Total Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1</td>
<td>526</td>
<td>579</td>
<td>1,105</td>
<td>0.25%</td>
</tr>
<tr>
<td>1-4</td>
<td>2,699</td>
<td>2,908</td>
<td>5,607</td>
<td>1.28%</td>
</tr>
<tr>
<td>5-14</td>
<td>9,745</td>
<td>10,498</td>
<td>20,243</td>
<td>4.60%</td>
</tr>
<tr>
<td>15-24</td>
<td>11,535</td>
<td>11,063</td>
<td>22,598</td>
<td>5.14%</td>
</tr>
<tr>
<td>25-44</td>
<td>17,257</td>
<td>13,773</td>
<td>31,030</td>
<td>7.07%</td>
</tr>
<tr>
<td>45-64</td>
<td>57,257</td>
<td>31,280</td>
<td>88,537</td>
<td>20.14%</td>
</tr>
<tr>
<td>65-74</td>
<td>83,186</td>
<td>74,229</td>
<td>157,415</td>
<td>35.81%</td>
</tr>
<tr>
<td>75+</td>
<td>69,167</td>
<td>43,809</td>
<td>112,976</td>
<td>25.71%</td>
</tr>
<tr>
<td>Total</td>
<td>251,490</td>
<td>188,139</td>
<td>439,629</td>
<td>100%</td>
</tr>
<tr>
<td>% of Total Population</td>
<td>57.2%</td>
<td>42.8%</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>
Burden of Proof:
The 90% Confidence Interval?

- **Current Standards:**

  - **Relative Mean AUC:**
    - the 90% CI of the relative mean AUC of the T to the R formulation should be within 80-125%; AUC may be evaluated by determining $\text{AUC}_T$ provided that $\text{AUC}_T/\text{AUC}_I \geq 0.80$

  - **Relative Mean $C_{\text{max}}$:**
    - the relative mean measured $C_{\text{max}}$ of the T to the R formulation should be between 80-125%
Average vs Individual Bioequivalence

**Average Bioequivalence:**
- does not address the right question i.e. ‘switchability’
- does not take into account subject by formulation interaction
- no incentive to create a less variable T formulation
- does not encourage use of subjects that are representative of the target population

**Individual Bioequivalence:**
- attractive from a clinical point of view but practical and methodological issues must be overcome
Number of Brand Name Authorizations for the Alberta Health Sponsored Drug Programs 1993-1997

<table>
<thead>
<tr>
<th>Year</th>
<th>Brand Name Requests</th>
<th>Approved</th>
<th>Declined</th>
<th>Approval Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1993</td>
<td>167</td>
<td>121</td>
<td>46</td>
<td>72.5%</td>
</tr>
<tr>
<td>1993</td>
<td>167 (3 months)</td>
<td>167</td>
<td>46</td>
<td>72.5%</td>
</tr>
<tr>
<td>1994</td>
<td>431</td>
<td>260</td>
<td>171</td>
<td>60.3%</td>
</tr>
<tr>
<td>1995</td>
<td>186</td>
<td>96</td>
<td>90</td>
<td>51.6%</td>
</tr>
<tr>
<td>1996</td>
<td>185</td>
<td>65</td>
<td>120</td>
<td>35.1%</td>
</tr>
<tr>
<td>1997</td>
<td>87</td>
<td>38</td>
<td>49</td>
<td>43.7%</td>
</tr>
<tr>
<td>Total</td>
<td>1056</td>
<td>580</td>
<td>476</td>
<td>54.9%</td>
</tr>
</tbody>
</table>

- *Is there evidence to support a problem with the current interchange of drugs?*
From the Formulary Perspective:

- do equivalent plasma concentrations mean equivalent therapeutic effect and safety?

- to what extent are minor differences in formulations exaggerated in special populations?

- should bioequivalence be determined at only one point in a product’s lifetime i.e. formulation creep?

- to what extent should the legislators and policy makers be involved?